166 related articles for article (PubMed ID: 37713162)
21. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
22. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
23. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
Cabanillas ME; Ferrarotto R; Garden AS; Ahmed S; Busaidy NL; Dadu R; Williams MD; Skinner H; Gunn GB; Grosu H; Iyer P; Hofmann MC; Zafereo M
Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
[TBL] [Abstract][Full Text] [Related]
24. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.
Gibson WJ; Ruan DT; Paulson VA; Barletta JA; Hanna GJ; Kraft S; Calles A; Nehs MA; Moore FD; Taylor-Weiner A; Wala JA; Zack TI; Lee TC; Fennessy FM; Alexander EK; Thomas T; Janne PA; Garraway LA; Carter SL; Beroukhim R; Lorch JH; Van Allen EM
Clin Cancer Res; 2017 May; 23(9):2367-2373. PubMed ID: 27797976
[No Abstract] [Full Text] [Related]
25. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
26. Mutation based approaches to the treatment of anaplastic thyroid cancer.
McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
[TBL] [Abstract][Full Text] [Related]
27. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract][Full Text] [Related]
28. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
29. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
30. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Liu R; Liu D; Xing M
J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
[TBL] [Abstract][Full Text] [Related]
31. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
32. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
33. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
34. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
35. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
[TBL] [Abstract][Full Text] [Related]
36. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
37. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
38. Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response.
Hu H; Ng TSC; Kang M; Scott E; Li R; Quintana JM; Matvey D; Vantaku VR; Weissleder R; Parangi S; Miller MA
Clin Cancer Res; 2023 Sep; 29(17):3457-3470. PubMed ID: 37289199
[TBL] [Abstract][Full Text] [Related]
39. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
40. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]